Free choice of purification conditions and enhanced protein stabilization in a pre-packed format
Penzberg, Germany, June 26, 2013 / B3C newswire / - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its new cOmplete His-Tag Purification Column for researchers performing histidine-tagged protein purification from lysates. The new column uses Roche’s proprietary nickel-chelate chemistry and is compatible with commonly used reducing agents (DTT), metalloproteinase inhibiting reagents such as EDTA, and different buffer and salt environments. This allows researchers to choose optimal buffer conditions for the target protein in a convenient pre-packed format.
“We have received very positive feedback from pilot users who appreciate the flexibility of being able to purify proteins under protein protecting conditions,” said Ruedi Stoffel, Head of Biochemical Reagents & Custom Biotech. “It enables our customers to apply any buffer required to obtain proteins of high purity, stability and function.”
Following the purification step, the new column does not require buffer exchange or resin recharging therefore avoiding a costly and time consuming process. In addition, the resin’s minimized nickel ion leakage not only reduces toxic nickel waste, but also stabilizes the target protein by preventing nickel ions from catalyzing protein oxidation.
Thanks to the additional format, researchers can choose their preferred method of purification. The cOmplete His-Tag Purification Resin can be used for batch purification as well as on automated systems based on FPLC. Pre-packed cOmplete His-Tag Purification Columns are available in two sizes (1 ml and 5 ml) and are compatible with standard instruments for protein purification.
Visit www.complete.roche.com for more information.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
COMPLETE is a trademark of Roche.
All other product names and trademarks are the property of their respective owners.
For life science research only. Not for use in diagnostic procedures.
For further information please contact:
Dr. Claudia Schmitt
Phone: +49 8856 60 10210